Hikari Power’s Sarepta Therapeutics SRPT Stock Holding History

Hikari Power’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,000	Closed	-$1.61M	–	131
2018 Q3	$1.61M	Hold	10,000	–	–	0.16%	60
2018 Q2	$1.32M	Sell	10,000 -15,000	-60%	-$1.41M	0.15%	63
2018 Q1	$1.85M	Hold	25,000	–	–	0.22%	48
2017 Q4	$1.39M	Hold	25,000	–	–	0.16%	53
2017 Q3	$1.13M	Buy	+25,000	New	+$999K	0.15%	57

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Hikari Power's SRPT Position: Q4 2018 in Review

Hikari Power sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 10,000 shares — an estimated $1.61M sold.

Hikari Power first reported a position in SRPT in Q3 2017 and held it in 5 quarters. The position peaked at $1.85M in Q1 2018. 335 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

Hikari Power reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
Hikari Power sold 10,000 Sarepta Therapeutics shares in Q4 2018, an estimated $1.61M.
Hikari Power first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 5 quarters.
Hikari Power's Sarepta Therapeutics position peaked at $1.85M in Q1 2018.
335 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Hikari Power's 13F filing for Q4 2018, filed 29 Jan 2019.